Pilot Plant Scale-Up of Oral Solid Dosage Forms Using Quality by Design (QbD)

Abstract

The scale-up of oral solid dosage forms from laboratory to pilot plant scale is a critical phase in pharmaceutical product development. Traditional scale-up approaches often rely on empirical adjustments, which may lead to variability in product quality and manufacturing inefficiencies. Quality by Design (QbD) offers a systematic, science-based, and risk-oriented framework to ensure consistent product quality during scale-up. This paper presents a comprehensive draft on the application of QbD principles in pilot plant scale-up of oral solid dosage forms, focusing on critical quality attributes (CQAs), critical material attributes (CMAs), critical process parameters (CPPs), risk assessment, design space development, and control strategies. The integration of QbD into pilot-scale operations enhances process understanding, reduces scale-up failures, and supports regulatory compliance.

Keywords

Introduction

Fig. 1 Pilot Plant Scale-Up

Quality by Design (QbD), as defined by the International Council for Harmonisation (ICH) guidelines Q8 (Pharmaceutical Development), Q9 (Quality Risk Management), and Q10 (Pharmaceutical Quality System), provides a systematic and science-based approach to pharmaceutical development. QbD emphasizes a thorough understanding of the relationship between critical material attributes (CMAs), critical process parameters (CPPs), and CQAs to ensure that quality is built into the product from the early stages of development rather than being tested into the final product.[3,4]

The application of QbD principles during pilot plant scale-up enables the establishment of a Quality Target Product Profile (QTPP), identification of CQAs through risk assessment tools such as Failure Mode and Effects Analysis (FMEA) and Ishikawa diagrams, and systematic optimization using Design of Experiments (DoE). This approach facilitates the development of a design space, within which process parameters can vary without compromising product quality. Operating within the approved design space offers greater manufacturing flexibility and reduces the need for post-approval regulatory submissions.[5]

Furthermore, QbD-based scale-up supports process robustness, reproducibility, and lifecycle management, ensuring smoother technology transfer from pilot plant to commercial manufacturing. It also aligns with regulatory expectations by promoting enhanced product understanding, reduced variability, continuous improvement, and real-time quality assurance. Consequently, the integration of QbD principles in pilot plant scale-up of oral solid dosage forms significantly enhances product quality, process efficiency, and regulatory compliance, ultimately leading to safer and more effective pharmaceutical products for patients.[6]

2. PILOT PLANT SCALE-UP: AN OVERVIEW

The pilot plant serves as a critical transitional stage between laboratory-scale formulation development and full-scale commercial manufacturing. It bridges the gap by allowing systematic evaluation of formulation and process variables under conditions that closely resemble commercial production. The primary objectives of a pilot plant include:

• Simulating commercial-scale manufacturing conditions to assess process robustness
• Identifying scale-dependent process challenges and variability
• Optimizing equipment selection, operating parameters, and material flow behavior
• Establishing critical process parameters (CPPs) and critical quality attributes (CQAs)
• Generating reproducible and scientifically justified data for regulatory submissions and technology transfer[7]

Pilot plant scale-up typically involves batch sizes ranging from 10 to 100 times the laboratory scale, although the exact scale depends on dosage form, equipment availability, and regulatory expectations. This stage allows manufacturers to evaluate process feasibility, reproducibility, and control strategies before committing to large-scale production.[8]

For oral solid dosage forms, pilot plant operations encompass several sequential and interdependent unit operations, including blending, granulation, drying, milling, lubrication, compression, and coating. Each of these unit operations must be carefully scaled while maintaining product quality and performance.

• Blending: Ensures uniform distribution of active pharmaceutical ingredients (APIs) and excipients. Scale-up considerations include blender type, fill level, mixing time, and powder flow properties.
• Granulation: Performed using wet or dry granulation techniques to improve flowability and compressibility. Pilot-scale granulation helps optimize binder concentration, granulation time, and impeller speed.
• Drying: Reduces residual moisture to acceptable limits. Drying kinetics may vary with scale due to heat and mass transfer differences, requiring optimization of temperature, airflow, and drying time.
• Milling: Achieves desired particle size distribution, which directly impacts dissolution, content uniformity, and compressibility.
• Lubrication: Enhances tablet ejection and prevents sticking during compression. Over- or under-lubrication risks can be evaluated effectively at the pilot scale.
• Compression: Critical parameters such as compression force, turret speed, and dwell time are optimized to ensure tablet hardness, friability, and weight uniformity.
• Coating: Pilot-scale coating studies help optimize spray rate, inlet air temperature, pan speed, and coating uniformity while minimizing defects such as picking and mottling.

Additionally, pilot plant studies play a crucial role in process validation readiness, equipment qualification, and risk assessment under Quality by Design (QbD) principles. Data generated at this stage supports scale-up decisions, process optimization, and regulatory compliance, ultimately reducing the risk of product failure during commercial manufacturing.[9]

3. QUALITY BY DESIGN (QBD): CONCEPT AND REGULATORY PERSPECTIVE

Quality by Design (QbD) is a systematic, science- and risk-based approach to pharmaceutical development that begins with predefined objectives and emphasizes thorough product and process understanding along with quality risk management. Unlike traditional quality approaches that rely primarily on end-product testing, QbD focuses on building quality into the product from the early stages of development.[10]

According to the International Council for Harmonisation (ICH) guideline Q8 (R2), QbD aims to ensure consistent product quality by identifying sources of variability and controlling them throughout the product lifecycle. The implementation of QbD promotes robust manufacturing processes, minimizes batch failures, and improves regulatory confidence.

From a regulatory perspective, agencies such as the US FDA, EMA, and CDSCO actively encourage the adoption of QbD principles as it enhances scientific understanding, supports regulatory flexibility, and enables continuous improvement without compromising product quality.[11]

3.1 Key Elements of Quality by Design

3.1.1 Quality Target Product Profile (QTPP)

The QTPP is a prospective summary of the quality characteristics of a drug product that ideally will be achieved to ensure desired safety and efficacy. It includes dosage form, route of administration, strength, release characteristics, stability, and patient compliance considerations.[12]

3.1.2 Critical Quality Attributes (CQAs)

CQAs are physical, chemical, biological, or microbiological properties that must be controlled within predefined limits to ensure product quality. Examples for oral solid dosage forms include assay, content uniformity, dissolution rate, hardness, friability, and impurity levels.

3.1.3 Critical Material Attributes (CMAs)

CMAs refer to material-related properties of APIs and excipients that can influence CQAs. These include particle size distribution, polymorphic form, moisture content, flow properties, and bulk density. Understanding CMAs is essential for raw material selection and supplier qualification.[13]

3.1.4 Critical Process Parameters (CPPs)

CPPs are process parameters whose variability can impact CQAs and therefore must be monitored or controlled. In tablet manufacturing, examples include mixing time, granulation endpoint, drying temperature, compression force, and coating spray rate.

3.1.5 Risk Assessment

Risk assessment is a cornerstone of QbD and is performed using systematic tools such as Failure Mode and Effects Analysis (FMEA), Ishikawa (fishbone) diagrams, and Hazard Analysis and Critical Control Points (HACCP). Risk assessment helps prioritize variables and focus development efforts on high-risk factors.[14]

3.1.6 Design Space

Design space is defined as the multidimensional combination and interaction of input variables and process parameters that have been demonstrated to assure product quality. Operation within the approved design space is not considered a regulatory change, offering flexibility during manufacturing.

3.1.7 Control Strategy

The control strategy consists of planned controls derived from process understanding, including raw material controls, in-process controls, finished product specifications, and process monitoring. An effective control strategy ensures consistent performance and regulatory compliance.

3.1.8 Lifecycle Management

Lifecycle management involves continuous monitoring and improvement of the product and process throughout its commercial life. It aligns with ICH Q10 (Pharmaceutical Quality System) and supports post-approval changes based on accumulated knowledge and performance data.[15]

4. QUALITY TARGET PRODUCT PROFILE (QTPP)

The Quality Target Product Profile (QTPP) is a prospective summary of the quality characteristics that a pharmaceutical product should possess to ensure its intended safety, efficacy, and quality throughout its lifecycle. Within the Quality by Design (QbD) framework, the QTPP serves as the starting point for rational product development and provides a clear link between patient needs, clinical performance, and manufacturing considerations.[20,16]

Regulatory guidelines, particularly ICH Q8 (R2), emphasize the importance of defining the QTPP early in development to guide formulation design, process optimization, and risk assessment activities. A well-defined QTPP helps ensure that product development is patient-centric and aligned with regulatory expectations.[17]

For oral solid dosage forms, the QTPP typically includes the following key elements:

• Dosage form and strength: Specifies the type of dosage form (tablet or capsule) and the intended drug strength(s), ensuring dose accuracy and patient convenience.
• Route of administration: Generally oral, with considerations for ease of administration and patient compliance.
• Release characteristics: Defines whether the formulation is immediate release, delayed release, or modified/controlled release, which directly influences therapeutic performance and dosing frequency.
• Stability and shelf life: Establishes the intended shelf life under recommended storage conditions, considering physical, chemical, and microbiological stability.
• Bioavailability: Ensures adequate and reproducible drug absorption to achieve the desired therapeutic effect.
• Appearance and organoleptic properties: Includes tablet size, shape, color, taste, and odor, which influence patient acceptability and compliance.[18]

The QTPP also considers packaging requirements, administration frequency, and target patient population, particularly for special populations such as pediatric or geriatric patients.

Importantly, the QTPP acts as the foundation for identifying Critical Quality Attributes (CQAs). Each element of the QTPP is systematically translated into measurable quality attributes that must be controlled during formulation and manufacturing. Thus, the QTPP not only defines the desired end product but also guides formulation selection, process development, risk assessment, and control strategy design.[19]

5. CRITICAL QUALITY ATTRIBUTES (CQAS)

Critical Quality Attributes (CQAs) are physical, chemical, biological, or microbiological characteristics that must be controlled within predefined limits to ensure that the pharmaceutical product consistently meets its intended quality, safety, and efficacy. According to ICH Q8 (R2), a CQA is any attribute that has a direct impact on the Quality Target Product Profile (QTPP).[21]

The identification of CQAs is a key step in the Quality by Design (QbD) approach, as it provides a scientific basis for linking formulation variables and process parameters to product performance. CQAs are established based on prior knowledge, risk assessment, and experimental studies.[22]

For oral solid dosage forms, commonly identified CQAs include:

• Assay and content uniformity: Ensure accurate and uniform distribution of the active pharmaceutical ingredient (API) within each dosage unit, which is critical for dose accuracy and therapeutic effectiveness.
• Dissolution profile: Reflects the rate and extent of drug release, serving as a surrogate for in vivo performance and bioavailability, particularly for immediate- and modified-release formulations.
• Hardness and friability: Indicate the mechanical strength of tablets, affecting their ability to withstand handling, packaging, and transportation without damage.
• Disintegration time: Ensures timely tablet breakdown in the gastrointestinal tract, which is essential for drug release and absorption in immediate-release products.
• Moisture content: Influences physical stability, chemical degradation, and microbial growth, especially in moisture-sensitive formulations.
• Tablet weight variation: Ensures dose uniformity and compliance with pharmacopeial specifications.[23]

During pilot plant scale-up, CQAs may be significantly influenced by changes in equipment size, processing time, mixing efficiency, heat and mass transfer, and environmental conditions such as temperature and humidity. Scale-dependent variations can alter granule properties, tablet density, and coating uniformity, potentially impacting final product quality.[24]

6. CRITICAL MATERIAL ATTRIBUTES (CMAS)

Critical Material Attributes (CMAs) are the physical, chemical, biological, or microbiological properties of active pharmaceutical ingredients (APIs) and excipients that have the potential to influence Critical Quality Attributes (CQAs) of the finished pharmaceutical product. Within the Quality by Design (QbD) framework, CMAs are identified through prior knowledge, experimental studies, and systematic risk assessment.[25]

According to ICH Q8 (R2), understanding and controlling CMAs is essential for ensuring consistent product quality and minimizing variability during manufacturing and scale-up.

For oral solid dosage forms, important CMAs include:

• Particle size distribution (PSD): Affects powder flow, blend uniformity, compressibility, dissolution rate, and bioavailability. Changes in PSD during scale-up can significantly impact tablet performance.
• Polymorphic form: Different crystalline forms of an API may exhibit variations in solubility, stability, and dissolution behavior, directly influencing bioavailability and shelf life.
• Flow properties: Characteristics such as angle of repose, Carr’s index, and Hausner ratio influence die filling, weight variation, and content uniformity during compression.
• Bulk and tapped density: Affect hopper flow, blending efficiency, and tablet weight control, especially during high-speed compression.
• Moisture content: Plays a critical role in granulation behavior, tablet hardness, stability, and microbial control, particularly for hygroscopic materials.[26]

Additional CMAs may include excipient grade, surface area, porosity, and lubricant sensitivity, all of which can affect product performance and manufacturability.

During pilot plant scale-up, variability in raw material sources, supplier changes, lot-to-lot differences, and increased batch sizes can significantly influence CMAs. Such variability may lead to changes in granule characteristics, tablet mechanical strength, dissolution behavior, and stability profiles.[27]

Therefore, strict control of CMAs through material specifications, supplier qualification, incoming raw material testing, and change management systems is essential. Understanding the relationship between CMAs and CQAs enables the identification of Critical Process Parameters (CPPs) and supports the development of a robust control strategy, ensuring successful scale-up and consistent commercial manufacturing.[28]

7. CRITICAL PROCESS PARAMETERS (CPPS)

Critical Process Parameters (CPPs) are process variables whose variability has a direct and significant impact on Critical Quality Attributes (CQAs) and, therefore, must be monitored and controlled to ensure consistent product quality. As defined in ICH Q8 (R2), a CPP is a parameter that, when varied beyond a defined range, can adversely affect the quality of the finished pharmaceutical product.[29]

Identification of CPPs is achieved through process understanding, risk assessment, and experimental evaluation, particularly during pilot plant scale-up, where process behavior at increased batch sizes can be systematically studied.[30]

For oral solid dosage forms, commonly identified CPPs include:

• Blending time and speed: Influence content uniformity and blend homogeneity. Over-blending or under-blending may result in segregation or inadequate API distribution.
• Granulation endpoint: Determines granule size, density, and strength. Inappropriate granulation endpoints can lead to poor flow, compressibility issues, and variability in dissolution.
• Drying temperature and time: Affect residual moisture content, granule stability, and downstream processing performance. Excessive drying may cause brittle granules, while insufficient drying can lead to sticking and stability issues.
• Milling speed and screen size: Control particle size distribution, which directly influences flow properties, compaction behavior, and dissolution rate.
• Compression force and turret speed: Impact tablet hardness, friability, thickness, and disintegration time. Changes in dwell time at higher speeds can significantly affect tablet quality during scale-up.
• Coating parameters: Including spray rate, inlet air temperature, atomization air pressure, and pan speed, which influence coating uniformity, film integrity, and aesthetic quality.

Understanding the interrelationship between CPPs and CQAs is critical for developing a robust and scalable manufacturing process. During pilot-scale operations, Design of Experiments (DoE) is often employed to study the effects and interactions of CPPs, enabling the establishment of acceptable operating ranges and contributing to the definition of a design space.[31]

Effective control of CPPs during pilot plant scale-up ensures process consistency, reduced variability, and smooth transition to commercial-scale manufacturing, while also supporting regulatory flexibility and lifecycle management.[32]

8. RISK ASSESSMENT IN PILOT PLANT SCALE-UP

Risk assessment is a core component of Quality by Design (QbD) and plays a vital role in the successful scale-up of pharmaceutical manufacturing processes at the pilot plant level. In accordance with ICH Q9 (Quality Risk Management), risk assessment provides a systematic and science-based approach to identifying, analyzing, and controlling potential sources of variability that may impact product quality during scale-up.[33]

During pilot plant scale-up, changes in equipment size, processing conditions, material handling, and environmental factors can introduce new risks that were not evident at the laboratory scale. Therefore, structured quality risk management tools are employed to evaluate and prioritize these risks effectively.[34]

Commonly used risk assessment tools include:

• Failure Mode and Effects Analysis (FMEA): Identifies potential failure modes within a process, evaluates their severity, occurrence, and detectability, and assigns a risk priority number (RPN) to prioritize mitigation efforts.
• Ishikawa (fishbone) diagrams: Provide a visual representation of potential causes of variability related to materials, methods, equipment, environment, personnel, and measurement systems.
• Risk ranking and filtering matrices: Enable quantitative or semi-quantitative comparison of risks to support decision-making and resource allocation.[35]

Risk assessment during pilot plant scale-up helps to:

• Identify high-risk CMAs and CPPs that have the greatest potential impact on Critical Quality Attributes (CQAs)
• Focus experimental and developmental efforts on variables that are most likely to affect product quality
• Minimize scale-up failures by proactively addressing potential process weaknesses
• Enhance process robustness and reproducibility, ensuring consistent product quality across different scales[36]

The outcomes of risk assessment directly inform the design of Design of Experiments (DoE) studies, the establishment of and the development of an effective control strategy. Additionally, risk design space, assessment is a continuous activity that extends throughout the product lifecycle, supporting ongoing process optimization, change management, and regulatory compliance.[37]

9. DESIGN SPACE DEVELOPMENT

Design space is defined by ICH Q8 (R2) as the multidimensional combination and interaction of material attributes and process parameters that have been demonstrated to provide assurance of product quality. Operating within an approved design space is not considered a regulatory change, thereby offering significant flexibility in manufacturing operations.[38]

During pilot plant scale-up, the establishment of a design space is particularly critical, as it enables a comprehensive understanding of how Critical Material Attributes (CMAs) and Critical Process Parameters (CPPs) interact to influence Critical Quality Attributes (CQAs) at increased batch sizes. The pilot scale provides an optimal environment to evaluate these interactions under conditions that closely resemble commercial manufacturing.[39]

The development of a robust design space during pilot plant scale-up provides several advantages, including:

• Operational flexibility: Allows manufacturers to adjust process parameters within defined ranges without compromising product quality.
• Reduced regulatory burden: Post-approval changes made within the approved design space generally do not require regulatory re-approval, facilitating efficient lifecycle management.
• Improved process understanding: Enhances knowledge of process behavior, variability, and interdependencies, leading to more robust and reproducible manufacturing processes.[40]

Design of Experiments (DoE) is a key statistical tool used to establish and verify the design space at the pilot scale. DoE enables systematic investigation of the effects of multiple variables and their interactions on CQAs using a minimal number of experimental runs. Commonly employed DoE approaches include factorial designs, fractional factorial designs, and response surface methodologies.[41]

Data generated from pilot-scale DoE studies are used to define acceptable operating ranges, identify critical interactions, and confirm process robustness. These studies form the scientific basis for regulatory submissions and support technology transfer to commercial-scale manufacturing.

Overall, design space development during pilot plant scale-up strengthens the QbD framework by linking material attributes, process parameters, and product quality, thereby ensuring consistent performance and regulatory compliance throughout the product lifecycle.[42]

10. CONTROL STRATEGY

A control strategy is a planned set of controls, derived from comprehensive product and process understanding, that ensures the manufacturing process consistently operates within the defined design space and produces a product meeting all Critical Quality Attributes (CQAs). In line with ICH Q8 (R2) and ICH Q10 (Pharmaceutical Quality System), an effective control strategy integrates material controls, process controls, and end-product testing to maintain product quality throughout the product lifecycle.[43]

During pilot plant scale-up, the control strategy is refined and validated under conditions that closely resemble commercial manufacturing. This stage provides critical insight into process variability and helps establish controls that are both effective and practical at larger scales.

A robust control strategy typically includes the following components:

• Raw material controls: Specifications and acceptance criteria for APIs and excipients, including control of Critical Material Attributes (CMAs) such as particle size distribution, polymorphic form, moisture content, and flow properties. Supplier qualification and incoming material testing are essential elements of this control level.
• In-process controls (IPCs): Monitoring and control of Critical Process Parameters (CPPs) during manufacturing operations, such as blending time, granulation endpoint, drying conditions, compression force, and coating parameters. IPCs enable early detection of deviations and prevent the production of out-of-specification batches.
• Process monitoring: Continuous or periodic monitoring of key process variables to ensure consistent performance and detect trends. Process monitoring supports process capability assessment and ongoing improvement.
• Finished product testing: Verification that the final product meets predefined specifications for assay, content uniformity, dissolution, mechanical strength, stability, and other CQAs.[44]

Advanced Process Analytical Technology (PAT) tools can be integrated at the pilot scale to enhance process monitoring and control. Techniques such as near-infrared (NIR) spectroscopy, Raman spectroscopy, and online particle size analysis enable real-time measurement of critical parameters, supporting real-time release testing (RTRT) and improved process understanding.[45]

11. CASE APPLICATION: QbD-BASED PILOT SCALE-UP OF TABLETS

In a typical tablet formulation, the implementation of Quality by Design (QbD) begins with the systematic definition of the Quality Target Product Profile (QTPP), which outlines the intended dosage form, strength, release characteristics, bioavailability, and stability requirements. Based on the QTPP, relevant Critical Quality Attributes (CQAs) such as assay, content uniformity, dissolution profile, hardness, friability, and disintegration time are identified.[46]

Subsequently, a risk assessment is conducted to evaluate the potential impact of Critical Material Attributes (CMAs) and Critical Process Parameters (CPPs) on the identified CQAs. Tools such as Failure Mode and Effects Analysis (FMEA) and Ishikawa diagrams are commonly employed to prioritize high-risk variables related to raw material properties, granulation conditions, drying parameters, and compression settings.

Based on the outcomes of risk assessment, Design of Experiments (DoE) studies are performed at the pilot scale to systematically evaluate the effects and interactions of selected CMAs and CPPs. Pilot-scale batches are then manufactured using optimized process parameters identified through DoE, ensuring operation within the defined design space. These studies allow assessment of process robustness under conditions representative of commercial manufacturing.[47]

The results of QbD-based pilot scale-up typically demonstrate:

• Improved content uniformity, attributed to optimized blending and granulation parameters
• Consistent dissolution profiles, reflecting controlled particle size distribution and compression conditions
• Enhanced mechanical strength with acceptable hardness and friability
• Reduced batch-to-batch variability, due to better understanding and control of critical variables

Compared to conventional trial-and-error scale-up approaches, the QbD-based strategy provides greater process predictability, enhanced regulatory confidence, and improved manufacturing efficiency. The knowledge generated during pilot-scale development supports technology transfer, process validation, and lifecycle management, ultimately leading to reliable commercial production of high-quality tablet dosage forms.[47]

12. ADVANTAGES OF QbD IN PILOT PLANT SCALE-UP

The implementation of Quality by Design (QbD) in pilot plant scale-up offers several significant advantages over conventional, empirical scale-up approaches. By integrating scientific understanding, risk-based decision-making, and systematic process optimization, QbD enhances both product quality and manufacturing efficiency.

Key advantages of applying QbD during pilot plant scale-up include:

• Enhanced process understanding: QbD facilitates a comprehensive understanding of the relationships between material attributes, process parameters, and product quality. This knowledge enables informed decision-making and robust process design during scale-up.
• Improved product quality and consistency: Systematic identification and control of Critical Quality Attributes (CQAs), Critical Material Attributes (CMAs), and Critical Process Parameters (CPPs) result in consistent product performance and reduced batch-to-batch variability.
• Reduced scale-up risks: Risk assessment tools and Design of Experiments (DoE) allow early identification and mitigation of potential scale-dependent challenges, minimizing the likelihood of process failures during commercial manufacturing.
• Regulatory flexibility and compliance: Operating within an approved design space provides regulatory flexibility, as adjustments made within this space are not considered regulatory changes. This supports compliance with guidelines such as ICH Q8, Q9, and Q10 and facilitates smoother regulatory submissions and approvals.
• Cost and time efficiency: By reducing rework, batch failures, and post-approval changes, QbD shortens development timelines and lowers manufacturing costs, leading to faster product development and improved resource utilization.[48]

13. CHALLENGES AND LIMITATIONS

Despite the significant advantages offered by Quality by Design (QbD) in pilot plant scale-up, its implementation is associated with several practical and operational challenges. These limitations may influence the extent and pace of QbD adoption, particularly in resource-constrained manufacturing environments.[49]

Key challenges and limitations include:

• Increased initial development cost: QbD requires upfront investment in experimental studies, Design of Experiments (DoE), advanced analytical tools, and pilot-scale trials. These initial costs may be higher compared to traditional trial-and-error approaches, especially during early development stages.
• Requirement for advanced statistical and technical expertise: Effective implementation of QbD demands multidisciplinary expertise, including formulation science, process engineering, statistics, and regulatory science. A lack of trained personnel can limit the proper application and interpretation of DoE, risk assessment, and process modeling.
• Extensive data generation and documentation: QbD-based development involves comprehensive data collection, analysis, and documentation to support design space justification, control strategy, and regulatory submissions. Managing large datasets and maintaining thorough documentation can be time-consuming and resource-intensive.
• Complexity of implementation: The integration of multiple QbD elements—such as CMAs, CPPs, CQAs, risk assessment, and PAT—can increase process complexity, particularly for organizations transitioning from conventional development approaches.
• Limited access to advanced technologies: Implementation of Process Analytical Technology (PAT) and real-time monitoring tools may be constrained by equipment availability and cost, especially at the pilot scale.

Despite these challenges, the long-term benefits of QbD—such as enhanced process robustness, reduced regulatory risk, and improved product quality—often outweigh the initial limitations. With appropriate training, phased implementation, and organizational commitment, QbD can be effectively integrated into pilot plant scale-up strategies.[50]

14. CONCLUSION

The application of Quality by Design (QbD) in the pilot plant scale-up of oral solid dosage forms provides a systematic, science-based, and risk-oriented framework for pharmaceutical development. By proactively identifying and controlling Critical Quality Attributes (CQAs), Critical Material Attributes (CMAs), and Critical Process Parameters (CPPs), QbD enables the development of robust, reproducible, and scalable manufacturing processes.

Implementation of QbD at the pilot scale enhances process understanding, reduces scale-up uncertainties, and ensures consistent product quality across different manufacturing scales. The integration of risk assessment, Design of Experiments (DoE), design space development, and control strategies facilitates a smoother and more predictable transition from laboratory-scale development to commercial manufacturing.

Furthermore, adoption of QbD principles aligns pharmaceutical development with regulatory expectations outlined in ICH Q8, Q9, and Q10, providing regulatory flexibility, supporting lifecycle management, and enabling continuous process improvement. Although QbD requires higher initial investment and technical expertise, its long-term benefits in terms of quality assurance, regulatory compliance, cost efficiency, and patient safety significantly outweigh these challenges.

In conclusion, the incorporation of QbD principles during pilot plant scale-up is not only a regulatory expectation but also an essential component of modern pharmaceutical development, ensuring the successful commercialization of high-quality oral solid dosage forms.

REFERENCES

1. Ghodke, D. V., et al. (2014). Quality by design: Revised approach in pharmaceutics. International Journal of Universal Pharmacy and Life Sciences, 4(3), 45–56.
2. Nadpara, N. P., Thumar, R. V., & Kalola, V. N. (2012). Quality by design: A complete review. International Journal of Pharmaceutical Sciences Review and Research, 17(2), 20–28.
3. Rathore, A. S., & Winkle, H. (2009). Quality by design for biopharmaceuticals. Nature Biotechnology, 27(1), 26–34.
4. McCurdy, V. E. (2014). Process understanding for scale-up and manufacture of APIs. Wiley-VCH.
5. Trivedi, B. (2013). Quality by design in pharmaceutical sciences. International Journal of Pharmacy and Pharmaceutical Sciences, 5(2), 13–18.
6. U.S. Food and Drug Administration. (2006). Guidance for industry: Pharmaceutical development (Q8). FDA.
7. Singh, R., Rehman, Z., & Mishra, A. (2018). Analytical quality by design in pharmaceutical analysis. Journal of Pharmaceutical Analysis, 8(2), 91–101.
8. Prasad, S. K., Singh, S., & Patel, P. (2021). Pharmaceutical quality by design: Concepts, challenges, and applications. Journal of Pharmaceutical Research International, 33(52), 1–14.
9. Karanakov, L., et al. (2016). Critical review of ICH Q8, Q9, and Q10 from generic industry perspective. Macedonian Pharmaceutical Bulletin, 62(1), 23–30.
10. U.S. Food and Drug Administration. (2004). PAT—A framework for innovative pharmaceutical development, manufacturing, and quality assurance. FDA.
11. Yu, L. X., Amidon, G., Khan, M. A., Hoag, S. W., Polli, J., Raju, G. K., & Woodcock, J. (2014). Understanding pharmaceutical quality by design. AAPS Journal, 16(4), 771–783.
12. Fuloria, N. K., & Fuloria, S. (2012). Quality by design: An overview. International Journal of Drug Development and Research, 4(3), 1–10.
13. International Council for Harmonisation. (2005). ICH Q9: Quality risk management. ICH.
14. European Pharmaceutical Review. (2022). Quality by design: Omnipresence in the pharmaceutical product lifecycle. European Pharmaceutical Review.
15. FDA Guidance: Quality risk management (Q9). (2006). FDA.
16. Glodek, M., et al. (2011). Process robustness—A PQRI white paper. AAPS Journal, 13(4), 771–783.
17. Lionberger, R. A., Lee, S. L., Lee, L., Raw, A., & Yu, L. X. (2008). Quality by design: Concepts for ANDAs. AAPS Journal, 10(2), 268–276.
18. Nasr, M. M. (2013). Quality by design: Are we there yet? Pharmaceutical Research, 30(4), 1155–1156.
19. Nasr, M. (2010). Implementation of ICH Q8, Q9, and Q10: Regulatory perspective. FDA Workshop Proceedings.
20. International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development. ICH.
21. Nazzal, S., Khan, M. A., & Hussain, A. (2002). Response surface methodology for optimization of pharmaceutical formulations. International Journal of Pharmaceutics, 241(2), 179–187.
22. Aru, P. B., Rao, P. S., & Kumar, A. (2024). Quality by design in pharmaceutical development: A comprehensive review. GSC Biological and Pharmaceutical Sciences, 26(1), 1–15.
23. Juran, J. M. (1992). Juran on quality by design. Free Press.
24. Vanarase, A. U., & Muzzio, F. J. (2011). Effect of material attributes on tablet manufacture. AAPS PharmSciTech, 12(1), 238–250.
25. FDA Guidance: Pharmaceutical Quality System (Q10). (2009). FDA.
26. Patel, H., Patel, U., & Patel, K. (2017). Comprehensive review on quality by design in pharmaceuticals. International Journal of Pharmaceutical Sciences Review and Research, 45(1), 123–132.
27. U.S. Food and Drug Administration. (2006). Guidance for industry: Quality risk management (Q9). FDA.
28. Nasr, M., & McCurdy, V. (2010). QbD case studies: Accelerating time to market. AAPS Open, 1(2), 1–10.
29. Kovács, B., Nagy, Z. K., & Farkas, A. (2023). Quality-by-design in pharmaceutical development: A regulatory and scientific review. Acta Pharmaceutica Hungarica, 93(1), 1–12.
30. Bhise, J. J., Nalawade, A. M., & Gawali, S. S. (2019). A review on quality by design approach in pharmaceutical development. Journal of Drug Delivery and Therapeutics, 9(3), 563–570.
31. McCurdy, V. E., et al. (2010). Process understanding in pilot scale tablet manufacturing. Pharmaceutical Technology, 34(10), 54–60.
32. Sitre, D. S., & Kamble, R. D. (2020). Articulation of quality by design elements for pharmaceutical product development. Journal of Drug Delivery and Therapeutics, 10(5), 294–301.
33. ASTM International. (2016). ASTM E2281: Process capability and performance. ASTM.
34. Khan, M. A., & Hoag, S. W. (2012). Pilot scale studies in tablet manufacturing. Pharmaceutical Technology, 36(7), 54–60.
35. Raw, A. S., Lionberger, R. A., Yu, L. X., & FDA QbD Working Group. (2011). Pharmaceutical equivalence by design. Pharmaceutical Research, 28(5), 987–994.
36. Juran, J. M. (1992). Juran on quality by design. Free Press.
37. Bhise, J. J., Nalawade, A. M., & Gawali, S. S. (2019). A review on quality by design approach in pharmaceutical development. Journal of Drug Delivery and Therapeutics, 9(3), 563–570.
38. Blessy, M., Patel, R. D., Prajapati, P. N., & Agrawal, Y. K. (2014). Development of forced degradation and stability indicating studies of drugs—A review. Journal of Pharmaceutical Analysis, 4(3), 159–165.
39. Fuloria, N. K., & Fuloria, S. (2012). Quality by design: An overview. International Journal of Drug Development and Research, 4(3), 1–10.
40. Montgomery, D. C. (2017). Design and analysis of experiments (9th ed.). Wiley.
41. International Council for Harmonisation. (2012). ICH Q11: Development and manufacture of drug substances. ICH.
42. Lionberger, R. A., Lee, S. L., Lee, L., Raw, A., & Yu, L. X. (2008). Quality by design: Concepts for ANDAs. AAPS Journal, 10(2), 268–276.
43. Kourti, T., & MacGregor, J. F. (1996). Process analysis, monitoring, and diagnosis using multivariate statistical methods. Chemometrics and Intelligent Laboratory Systems, 28(1), 3–21.
44. Shewhart, W. A. (1931). Economic control of quality of manufactured product. D. Van Nostrand.
45. FDA Guidance: PAT—A framework for innovative pharmaceutical development. (2004). FDA.
46. European Medicines Agency. (2014). EMA–FDA QbD parallel assessment pilot report. EMA.
47. Ghodke, D. V., et al. (2014). Quality by design: Revised approach in pharmaceutics. International Journal of Universal Pharmacy and Life Sciences, 4(3), 45–56.
48. Nasr, M. M. (2013). Quality by design: Are we there yet? Pharmaceutical Research, 30(4), 1155–1156.
49. Patel, H., Patel, U., & Patel, K. (2017). Comprehensive review on quality by design in pharmaceuticals. International Journal of Pharmaceutical Sciences Review and Research, 45(1), 123–132.
50. International Society for Pharmaceutical Engineering. (2011). QbD best practices guide. ISPE.